GlassScriptPhysician profile
Karina Vasquez
NPI 1417191032
$8,411.79
in general payments reported to CMS, 2019-2025
34 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $378 · 2021: $845 · 2022: $1,283 · 2023: $1,395 · 2024: $1,867 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,250.07 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $702.38 | 2019-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $590.28 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $579.85 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $547.19 | 2020-2025 | |
| Vifor Pharma, INC. | $513.79 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $505.53 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $437.63 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $382.19 | 2022-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $351.73 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $275.09 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $272.14 | 2022-2025 | |
| Ardelyx, INC. | $265.80 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $254.24 | 2020-2025 | Benlysta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $195.93 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $166.03 | 2019-2025 | Envarsus |
| Cormedix INC. | $155.18 | 2024 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.15 | 2023-2025 | Jardiance |
| Shield Therapeutics INC | $139.42 | 2023-2025 | Accrufer |
| Akebia Therapeutics INC | $126.09 | 2024-2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $81.11 | 2024-2025 | Purified Cortrophin Gel |
| Outset Medical INC | $73.69 | 2022-2025 | |
| Lilly USA, LLC | $70.35 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $66.01 | 2025 | |
| Novo Nordisk INC | $49.19 | 2024 | Ozempic, Rybelsus |
| Mallinckrodt Enterprises LLC | $40.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.96 | 2022 | |
| Scpharmaceuticals INC. | $32.39 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.09 | 2023 | Gattex |
| Ascendis Pharma Endocrinology INC | $24.06 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $22.81 | 2025 | Verquvo |
| Ultragenyx Pharmaceutical INC. | $16.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.